Delivery Order SPE2DB25D3012-SPE2DB25FWYUH
- Not listed
- The Defense Logistics Agency awarded a $1,375.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 150 ml quantities. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by June 3, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,842.75 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,050.33 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,079.82. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 17, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,978.37 for Quillivant XR 25 mg/5 ml suspension (60 ml) with a firm fixed price structure. This non-set-aside, competitively awarded contract was executed on September 9, 2025, with an ultimate completion date of September 10, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a ceiling value of $1,301.87. This non-competitive, firm fixed-price delivery order is scheduled for completion by May 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract issued under a larger Indefinite Delivery Contract vehicle....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) at a firm fixed price of $1,681.44. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and is scheduled...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWYUHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL), valued at $1,631.48 under firm fixed-price terms. This is a non-set-aside competitive award with an ultimate completion date of July 24, 2025, and performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor within the Defense Logistics Agency's Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency and other federal healthcare systems. This award for Quillivant XR, a medication commonly used in the treatment of attention-deficit/hyperactivity disorder, demonstrates the company's ongoing capability to fulfill federal medical supply requirements through competitive procurement on behalf of military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 7/23/25 |